Abstract
Objectives: To assess mid-term outcome of biodegradable biliary stents (BBSs) to treat benign biliary strictures refractory to standard bilioplasty. Methods: Institutional review board approval was obtained and patient consent was waived. 107 patients (61 males, 46 females, mean age 59 ± 16 years), were treated. Technical success and complications were recorded. Ninety-seven patients (55 males, 42 females, aged 57 ± 17 years) were considered for follow-up analysis (mean follow-up 23 ± 12 months). Fisher’s exact test and Mann–Whitney U tests were used and a Kaplan–Meier curve was calculated. Results: The procedure was always feasible. In 2/107 cases (2 %), stent migration occurred (technical success 98 %). 4/107 patients (4 %) experienced mild haemobilia. No major complications occurred. In 19/97 patients (18 %), stricture recurrence occurred. In this group, higher rate of subsequent cholangitis (84.2 % vs. 12.8 %, p = 0.001) and biliary stones (26.3 % vs. 2.5 %, p = 0.003) was noted. Estimated mean time to stricture recurrence was 38 months (95 % C.I 34–42 months). Estimated stricture recurrence rate at 1, 2, and 3 years was respectively 7.2 %, 26.4 %, and 29.4 %. Conclusion: Percutaneous placement of a BBS is a feasible and safe strategy to treat benign biliary strictures refractory to standard bilioplasty, with promising results in the mid-term period. Key Points: • Percutaneous placement of a BBS is 100 % feasible. • The procedure appears free from major complications, with few minor complications. • BBSs offer promising results in the mid-term period. • With a BBS, external catheter/drainage can be removed early. • BBSs represent a new option in treating benign biliary stenosis.
| Original language | English |
|---|---|
| Pages (from-to) | 1-7 |
| Number of pages | 7 |
| Journal | European Radiology |
| DOIs | |
| Publication status | Accepted/In press - Mar 4 2016 |
Fingerprint
Keywords
- Biliary stricture
- Bioabsorbable biliary stent
- Percutaneous transhepatic bilioplasty
- Percutaneous transhepatic cholangiography
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Benign biliary strictures refractory to standard bilioplasty treated using polydoxanone biodegradable biliary stents : retrospective multicentric data analysis on 107 patients. / Mauri, Giovanni; Michelozzi, Caterina; Melchiorre, Fabio; Poretti, Dario; Pedicini, Vittorio; Salvetti, Monica; Criado, Eva; Falcò Fages, Joan; de Gregorio, Miguel Ángel; Laborda, Alicia; Sconfienza, Luca Maria; Cornalba, Gian Paolo; Monfardini, Lorenzo; Panek, Jiri; Tomas, Andrasina; Gimenez, Mariano.
In: European Radiology, 04.03.2016, p. 1-7.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Benign biliary strictures refractory to standard bilioplasty treated using polydoxanone biodegradable biliary stents
T2 - retrospective multicentric data analysis on 107 patients
AU - Mauri, Giovanni
AU - Michelozzi, Caterina
AU - Melchiorre, Fabio
AU - Poretti, Dario
AU - Pedicini, Vittorio
AU - Salvetti, Monica
AU - Criado, Eva
AU - Falcò Fages, Joan
AU - de Gregorio, Miguel Ángel
AU - Laborda, Alicia
AU - Sconfienza, Luca Maria
AU - Cornalba, Gian Paolo
AU - Monfardini, Lorenzo
AU - Panek, Jiri
AU - Tomas, Andrasina
AU - Gimenez, Mariano
PY - 2016/3/4
Y1 - 2016/3/4
N2 - Objectives: To assess mid-term outcome of biodegradable biliary stents (BBSs) to treat benign biliary strictures refractory to standard bilioplasty. Methods: Institutional review board approval was obtained and patient consent was waived. 107 patients (61 males, 46 females, mean age 59 ± 16 years), were treated. Technical success and complications were recorded. Ninety-seven patients (55 males, 42 females, aged 57 ± 17 years) were considered for follow-up analysis (mean follow-up 23 ± 12 months). Fisher’s exact test and Mann–Whitney U tests were used and a Kaplan–Meier curve was calculated. Results: The procedure was always feasible. In 2/107 cases (2 %), stent migration occurred (technical success 98 %). 4/107 patients (4 %) experienced mild haemobilia. No major complications occurred. In 19/97 patients (18 %), stricture recurrence occurred. In this group, higher rate of subsequent cholangitis (84.2 % vs. 12.8 %, p = 0.001) and biliary stones (26.3 % vs. 2.5 %, p = 0.003) was noted. Estimated mean time to stricture recurrence was 38 months (95 % C.I 34–42 months). Estimated stricture recurrence rate at 1, 2, and 3 years was respectively 7.2 %, 26.4 %, and 29.4 %. Conclusion: Percutaneous placement of a BBS is a feasible and safe strategy to treat benign biliary strictures refractory to standard bilioplasty, with promising results in the mid-term period. Key Points: • Percutaneous placement of a BBS is 100 % feasible. • The procedure appears free from major complications, with few minor complications. • BBSs offer promising results in the mid-term period. • With a BBS, external catheter/drainage can be removed early. • BBSs represent a new option in treating benign biliary stenosis.
AB - Objectives: To assess mid-term outcome of biodegradable biliary stents (BBSs) to treat benign biliary strictures refractory to standard bilioplasty. Methods: Institutional review board approval was obtained and patient consent was waived. 107 patients (61 males, 46 females, mean age 59 ± 16 years), were treated. Technical success and complications were recorded. Ninety-seven patients (55 males, 42 females, aged 57 ± 17 years) were considered for follow-up analysis (mean follow-up 23 ± 12 months). Fisher’s exact test and Mann–Whitney U tests were used and a Kaplan–Meier curve was calculated. Results: The procedure was always feasible. In 2/107 cases (2 %), stent migration occurred (technical success 98 %). 4/107 patients (4 %) experienced mild haemobilia. No major complications occurred. In 19/97 patients (18 %), stricture recurrence occurred. In this group, higher rate of subsequent cholangitis (84.2 % vs. 12.8 %, p = 0.001) and biliary stones (26.3 % vs. 2.5 %, p = 0.003) was noted. Estimated mean time to stricture recurrence was 38 months (95 % C.I 34–42 months). Estimated stricture recurrence rate at 1, 2, and 3 years was respectively 7.2 %, 26.4 %, and 29.4 %. Conclusion: Percutaneous placement of a BBS is a feasible and safe strategy to treat benign biliary strictures refractory to standard bilioplasty, with promising results in the mid-term period. Key Points: • Percutaneous placement of a BBS is 100 % feasible. • The procedure appears free from major complications, with few minor complications. • BBSs offer promising results in the mid-term period. • With a BBS, external catheter/drainage can be removed early. • BBSs represent a new option in treating benign biliary stenosis.
KW - Biliary stricture
KW - Bioabsorbable biliary stent
KW - Percutaneous transhepatic bilioplasty
KW - Percutaneous transhepatic cholangiography
UR - http://www.scopus.com/inward/record.url?scp=84960082139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960082139&partnerID=8YFLogxK
U2 - 10.1007/s00330-016-4278-6
DO - 10.1007/s00330-016-4278-6
M3 - Article
SP - 1
EP - 7
JO - European Radiology
JF - European Radiology
SN - 0938-7994
ER -